

Special Issue

Targeted Cancer Therapy: Small Molecules and Immunotherapy

Message from the Guest Editor

Cancer remains the second leading cause of death and morbidity worldwide, with 9.6 million deaths in 2018. Conventional cytotoxic agents have low therapeutic index and frequently display toxicity in cells. The need for innovative chemotypes and the identification of new cancer-relevant targets therefore crucial. Besides recently developed materials and nanotechnologies, antibody-drug conjugates (ADCs) are still the current vehicles of choice for targeted delivery in Oncology. Over the last couple of years, the use of low molecular weight targeted agents, used as small molecule drug conjugates (SMDCs) has slowly established as a promising alternative to overcome ADCs' limitations. Exploiting new biomarkers for selective cancer imaging and targeted delivery of therapeutic agents (e.g., cytotoxic agents, small-molecule inhibitors, siRNA, immunomodulators) a pioneering and original means of defying several cancer types. This Special Issue intends to publish original and/or review articles covering the state of the art and future viewpoints of targeted therapies in cancer treatment.


Guest Editor

Prof. Dr. Marta Coimbra Marques

Instituto de Medicina Molecular João Lobo Antunes, 1649-028 Lisbon, Portugal

Deadline for manuscript submissions

closed (31 August 2024)



Molecules

an Open Access Journal
by MDPI

Impact Factor 4.6
CiteScore 8.6
Indexed in PubMed




mdpi.com/si/122928

Molecules
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
molecules@mdpi.com

[mdpi.com/journal/
molecules](https://mdpi.com/journal/molecules)





Molecules

an Open Access Journal
by MDPI

Impact Factor 4.6
CiteScore 8.6
Indexed in PubMed



[mdpi.com/journal/
molecules](https://mdpi.com/journal/molecules)



About the Journal

Message from the Editor-in-Chief

As the premier open access journal dedicated to experimental organic chemistry, and now in its 25th year of publication, the papers published in *Molecules* span from classical synthetic methodology to natural product isolation and characterization, as well as physicochemical studies and the applications of these molecules as pharmaceuticals, catalysts and novel materials. Pushing the boundaries of the discipline, we invite papers on multidisciplinary topics bridging biochemistry, biophysics and materials science, as well as timely reviews and topical issues on cutting edge fields in all these areas.

Editor-in-Chief

Prof. Dr. Thomas J. Schmidt

Institute of Pharmaceutical Biology and Phytochemistry, University of Münster, Corrensstrasse 48, D-48149 Münster, Germany

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, MEDLINE, PMC, Reaxys, CaPlus / SciFinder, MarinLit, AGRIS, and other databases.

Journal Rank:

JCR - Q2 (Biochemistry and Molecular Biology) / CiteScore - Q1 (Organic Chemistry)

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 16.1 days after submission; acceptance to publication is undertaken in 2.6 days (median values for papers published in this journal in the first half of 2025).